Liwei Bao

1.1k total citations
30 papers, 847 citations indexed

About

Liwei Bao is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Liwei Bao has authored 30 papers receiving a total of 847 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 14 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Liwei Bao's work include Cancer Cells and Metastasis (12 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Liwei Bao is often cited by papers focused on Cancer Cells and Metastasis (12 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Liwei Bao collaborates with scholars based in United States, China and Hong Kong. Liwei Bao's co-authors include Sofía D. Merajver, Steven G. Allen, Zhifen Wu, Weiqiang Chen, Jianping Fu, Raymond H. W. Lam, Feng Zhang, Shinuo Weng, Jill A. Macoska and Joel A. Yates and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Liwei Bao

29 papers receiving 838 citations

Peers

Liwei Bao

ONCOL

IMMUN

Misato Takigahira Japan

Thinzar M. Lwin United States

Clifton Stephens United States

Diane M. Boucher United States

Maïté Verreault France

Jennifer A. Roth United States

Fabio Cerignoli United States

Rafał Sądej Poland

Christopher M. Fife Australia

Misato Takigahira Japan

Liwei Bao

419 ×1.0

316 ×0.9

ONCOL

136 ×0.6

172 ×1.2

86 ×0.9

IMMUN

Citations per year, relative to Liwei Bao Liwei Bao (= 1×) peers Misato Takigahira

Countries citing papers authored by Liwei Bao

Since Specialization

Citations

This map shows the geographic impact of Liwei Bao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liwei Bao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liwei Bao more than expected).

Fields of papers citing papers by Liwei Bao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liwei Bao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liwei Bao. The network helps show where Liwei Bao may publish in the future.

Co-authorship network of co-authors of Liwei Bao

This figure shows the co-authorship network connecting the top 25 collaborators of Liwei Bao. A scholar is included among the top collaborators of Liwei Bao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liwei Bao. Liwei Bao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bao, Liwei. (2025). Mesenchymal stem cells in injury repair of vital organs: from mechanism to clinical application. PubMed. 14(2). 53–72. 1 indexed citations

Zhang, Xia, Peng Peng, Liwei Bao, et al.. (2024). Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression by Stabilizing c-MYC. Cells. 13(21). 1798–1798. 5 indexed citations

Bao, Liwei, Cheng Xu, Zhaoping Qin, et al.. (2024). Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion. npj Breast Cancer. 10(1). 43–43. 17 indexed citations

Morikawa, Aki, Aaron M. Udager, Liwei Bao, et al.. (2023). Personalized medicine for brain metastases (BrMets) through patient-derived organoid (PDO) drug testing.. JCO Global Oncology. 9(Supplement_1). 11–11.

Yates, Joel A., Megan Altemus, Liwei Bao, et al.. (2023). Blood–Brain Barrier Remodeling in an Organ‐on‐a‐Chip Device Showing Dkk1 to be a Regulator of Early Metastasis. SHILAP Revista de lepidopterología. 3(4). 9 indexed citations

Chen, Yuru, Shamileh Fouladdel, Harrison Ball, et al.. (2023). Abstract 5592: Expansion and characterization on ALK positive NSCLC circulating tumor cells isolated using a size based inertial microfluidic Labyrinth device. Cancer Research. 83(7_Supplement). 5592–5592. 1 indexed citations

Ulintz, Peter, Joel A. Yates, Andrew C. Little, et al.. (2021). RhoC Modulates Cell Junctions and Type I Interferon Response in Aggressive Breast Cancers. Frontiers in Oncology. 11. 712041–712041. 3 indexed citations

Yong, Koh Meng Aw, Peter Ulintz, Sara Cáceres, et al.. (2020). Heterogeneity at the invasion front of triple negative breast cancer cells. Scientific Reports. 10(1). 5781–5781. 19 indexed citations

Little, Andrew C., Zhifen Wu, Liwei Bao, et al.. (2019). IL-4/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion Via Rho-GTPase Regulation of Synergistic VEGF/CCL-18 Signaling. Frontiers in Oncology. 9. 456–456. 84 indexed citations

10.

Ulintz, Peter, Liwei Bao, John P. Lloyd, et al.. (2019). Molecular determinants of drug response in TNBC cell lines. Breast Cancer Research and Treatment. 179(2). 337–347. 8 indexed citations

11.

Rosselli‐Murai, Luciana K., Joel A. Yates, Sei Yoshida, et al.. (2018). Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. Journal of Cell Science. 131(8). 30 indexed citations

12.

Tiruchinapally, Gopinath, Yasemin Yüksel Durmaz, Liwei Bao, et al.. (2018). Synergistic inhibition of aggressive breast cancer cell migration and invasion by cytoplasmic delivery of anti-RhoC silencing RNA and presentation of EPPT1 peptide on “smart” particles. Journal of Controlled Release. 289. 79–93. 13 indexed citations

13.

Wynn, Michelle L., Joel A. Yates, Charles R. Evans, et al.. (2016). RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells. Journal of Biological Chemistry. 291(26). 13715–13729. 27 indexed citations

14.

Allen, Steven G., Yu‐Chih Chen, Julie Madden, et al.. (2016). Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC GTPase Signaling. Scientific Reports. 6(1). 39190–39190. 41 indexed citations

15.

Chen, Weiqiang, Steven G. Allen, Ajaya Kumar Reka, et al.. (2016). Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics. BMC Cancer. 16(1). 614–614. 23 indexed citations

16.

Rosenthal, Devin T., Jie Zhang, Liwei Bao, et al.. (2012). RhoC Impacts the Metastatic Potential and Abundance of Breast Cancer Stem Cells. PLoS ONE. 7(7). e40979–e40979. 56 indexed citations

17.

Chen, Weiqiang, Shinuo Weng, Feng Zhang, et al.. (2012). Nanoroughened Surfaces for Efficient Capture of Circulating Tumor Cells without Using Capture Antibodies. ACS Nano. 7(1). 566–575. 205 indexed citations

18.

Rosenthal, Devin T., Silvia Escudero, Liwei Bao, et al.. (2011). p38γ Promotes Breast Cancer Cell Motility and Metastasis through Regulation of RhoC GTPase, Cytoskeletal Architecture, and a Novel Leading Edge Behavior. Cancer Research. 71(20). 6338–6349. 49 indexed citations

19.

Rosenthal, Devin T., Silvia Escudero, Liwei Bao, et al.. (2010). Abstract 5193: p38 gamma is a novel driver of breast cancer metastasis by modulating cellular motility. Cancer Research. 70(8_Supplement). 5193–5193. 1 indexed citations

20.

Kaer, Luc Van, Liwei Bao, Kenneth J. Pienta, et al.. (2002). Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma. Neoplasia. 4(5). 373–379. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact